Guselkumab crushes skin disease in psoriatic arthritis patientsDecember 15, 2017Psoriatic ArthritisPsoriasis
FDA approves infliximab biosimilar Ixifi for all of Remicade’s indicationsDecember 14, 2017PsoriasisPsoriatic Arthritis
Interleukin-23 inhibition for psoriasis shows ‘wow’ factorDecember 11, 2017PsoriasisPsoriatic Arthritis
Arthritis prevalence higher than previously thought, especially in adults under 65December 5, 2017Psoriatic Arthritis
FDA approves IL-17A antagonist for treating psoriatic arthritisDecember 2, 2017Psoriatic ArthritisPsoriasis
Topical tapinarof heads for phase 3 in atopic dermatitis and psoriasisNovember 11, 2017PsoriasisPsoriatic Arthritis
Moderate psoriasis: the new frontier for systemic therapiesNovember 6, 2017Psoriatic ArthritisPsoriasis
Guselkumab tops adalimumab for psychiatric comorbidities in psoriasisOctober 31, 2017PsoriasisPsoriatic Arthritis
Psoriasis patients face higher risk of alcohol-related death – but lower suicide riskOctober 27, 2017PsoriasisPsoriatic Arthritis
Biosimilars poised to save $54 billion over the next decadeOctober 25, 2017Psoriatic ArthritisPsoriasis
